Compare Hims and Hers Health Inc (HIMS) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? Hims and Hers Health Inc trades at $27.31 (market cap $6.93B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Hinge Health Inc. Class A Common Stock is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| HIMS | HNGE | |
|---|---|---|
Market Cap | $6.93B | $8.48B |
Volume | 9,771,956 | 879,799 |
Sector | Health | Health |
52-Week High | $62.76 | $105.14 |
52-Week Low | $14.52 | $31.17 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $7.64B | $8.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HIMS trades at $29.71, down 3.04% today, amid ongoing securities class action lawsuits. The stock shows bullish technical signals with strong moving average support and key resistance at $32. Fundamentally, while revenue grew to $2.35B in 2025, the company posted a net loss of -$142M in 2026 with negative profit margins, though it maintains a solid gross margin of 68.4%.
The investment outlook is mixed: technical indicators suggest near-term upside potential toward the $32.17 consensus target, but fundamental weakness and legal overhangs pose significant risks. Analyst sentiment leans cautious with 65% hold ratings, reflecting concerns about profitability and regulatory challenges despite growth prospects.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
